Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Very early FDG-PET/CT–response adapted therapy for advanced-stage Hodgkin lymphoma
2011-005473-22Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of doxorubicin, bleomycin, vinblastine, dacarbazine, cyclophosphamide in classical Hodgkin lymphoma (cHL), sponsored by European Organisation for Research and Treatment of Cancer. Started Dec 2012; status: terminated.
02
Drugs
doxorubicinbleomycinvinblastinedacarbazinecyclophosphamide
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2011-005473-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005473-22.